Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | PER2 | O15055 | 1/20 | 0.42 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.42 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | GLI1 | P08151 | 1/20 | 0.40 |
| ▸ | GLI2 | P10070 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 3/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.40 |
| ▸ | F7 | P08709 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | F3 | P13726 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7482735 | 0.84 | PER2 (0.46) | SLC6A2SLC6A4SLC6A3MAOAPER2 | |
| SCHEMBL3335239 | 0.76 | AHR (0.50) | SLC6A2SLC6A4SLC6A3MAOACA1 | |
| SCHEMBL3836298 | 0.75 | AHR (0.50) | SLC6A2SLC6A4SLC6A3MAOACYP2A6 | |
| SCHEMBL8533738 | 0.73 | CA12 (0.53) | MAOACA12CA1CA2CA9 | |
| SCHEMBL31543740 | 0.73 | CA12 (0.49) | MAOACA12CA1CA2CA9 | |
| SCHEMBL12749605 | 0.73 | CA12 (0.49) | MAOACA12CA1CA2CA9 | |
| SCHEMBL21765905 | 0.73 | MAPT (0.45) | CA12CA1CA2CA9ALOX15 | |
| SCHEMBL9717426 | 0.71 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3MAOACYP2A6 | |
| SCHEMBL15253052 | 0.71 | MAOA (0.51) | SLC6A2SLC6A4SLC6A3MAOAGLI1 | |
| SCHEMBL3612090 | 0.71 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3MAOAPER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281114-A1 | INDOLYLALKYL DERIVATIVES OF PYRIMIDINYLPIPERAZINE AND METABOLITES THEREOF FOR TREATMENT OF ANXIETY, DEPRESSION, AND SEXUAL DYSFUNCTION | FABRE-KRAMER PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2009137733-A1 | INDOLYLALKYL DERIVATIVES OF PYRIMIDINYLPIPERAZINE AND METABOLITES THEREOF FOR TREATMENT OF ANXIETY, DEPRESSION, AND SEXUAL DYSFUNCTION | FABRE-KRAMER PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-5434154-A | Serotonin agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
| EP-0464558-B1 | Antimigraine alkoxypyrimidine derivatives | BRISTOL MYERS SQUIBB CO (US) | 1994-12-28 | — | — | EP | disclosed |
| US-5300506-A | Indole-3-alkyl derivatives of alkoxypyrimidinylpiperazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-04-05 | — | — | US | disclosed |
| EP-0464558-A1 | Antimigraine alkoxypyrimidine derivatives | Bristol-Myers Squibb Company (US) | 1992-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281114-A1 | INDOLYLALKYL DERIVATIVES OF PYRIMIDINYLPIPERAZINE AND METABOLITES THEREOF FOR TREATMENT OF ANXIETY, DEPRESSION, AND SEXUAL DYSFUNCTION | HTR5A, TPH2, IDO2 | SLC6A2 158/4885SLC6A4 104/4885SLC6A3 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.